The U.S. Department of Health and Human Services issued a progress report this week on its implementation of Project BioShield, a program that gives the department authorities to support, facilitate, ...

Sens. Joseph Lieberman (D-Conn.) and Orrin Hatch (R-Utah) in the next few months plan to propose legislation to provide pharmaceutical companies that develop products used to respond to a bioterrorist ...

Melissa Quinn previously worked for The Daily Signal as a senior news reporter. Seeking a more robust defense in the event of a bioterrorist attack on the United States, the Bush administration ...

Project BioShield was the federal government's $5.6 billion answer to the anthrax scare of 2001. But funds have been slowly distributed, and an anthrax treatment is bogged down in a rivalry between ...

{mosads}Following the events of 9/11, Congress enacted Project BioShield to expand the U.S. stockpile of medicines and vaccines, referred to as medical countermeasures, to protect against potential ...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has issued five awards totaling $4 million to fund the development of products that ...

House leaders are leaning toward adopting the Senate version of legislation enacting Project Bioshield, according to House and Senate aides -- a move that would accelerate passage of a measure to ...

Melissa Quinn previously worked for The Daily Signal as a senior news reporter. Congress and the Obama White House looked for billions of dollars a few years ago to offset the costs of a legal ...

Five years after anthrax attacks left five dead, sickened 17 and terrified America, millions of vaccine shots developed through cutting-edge genetic engineering were supposed to be filling a new ...

Federal public health officials said Thursday that they anticipate Congress will soon pass the Project Bioshield legislation, a sweeping bill designed to strengthen the nation's biological defenses ...

WASHINGTON, DC (April 4, 2003): Biotechnology companies are well suited to address the modest commercial opportunities offered by creating safer, more effective and less costly vaccines for biodefense ...